<unk>  is the second most common malignancy that occurs as a complication following solid organ<unk> ation (skin cancer is the most common). Less commonly,<unk>  occurs after hematopoietic stem cell<unk> ation. The incidence varies by the type of<unk> ation: the lowest rates are seen with bone marrow<unk> s and liver<unk> s. The highest rates of<unk>  are seen with lung and heart<unk> s, which is primarily due to the need for higher levels of immunosuppression. The incidence of<unk>  is highest in the first year after<unk> ation; roughly 80 percent of cases after<unk>  occur in the first year.<unk> ation of unmatched or mismatched HLA bone marrow also increase the risk of<unk> . The main risk factors for<unk>  are the degree of immune suppression and the presence of Epstein-Barr virus. Specifically, higher levels of T cell immunosuppression increase the risk<unk> . Individuals who have never been infected by the Epstein-Barr virus (EBV negative) who receive an organ from a donor with prior EBV infection are 24 times more likely to develop<unk> . Similarly, CMV mismatching (with a CMV negative recipient from a CMV positive donor) increases the risk of<unk> .
Post-transplant lymphoproliferative disorder
AIDS-related lymphoma
Transfusion-associated graft-versus-host disease
Thymoma-associated multiorgan autoimmunity
Splenic marginal zone lymphoma
Graft-versus-host disease
Diffuse infiltrative lymphocytosis syndrome
Immune reconstitution inflammatory syndrome